Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium channel protein type 1 subunit beta (SCN1B)
- Target
- SCN1B
- Molecular classification
- Ion channel regulatory subunit, Cell adhesion molecule, Voltage-gated sodium channel auxiliary subunit
01
Overview
Sodium channel protein type 1 subunit beta (SCN1B) is an auxiliary regulatory subunit of voltage-gated sodium channels, critical for modulating channel gating, kinetics, and localization in excitable tissues like neurons and muscle. The beta-1 subunit not only modulates the function of the sodium channel alpha subunit but also acts as a cell adhesion molecule involved in neuronal migration and pathfinding. Mutations in the SCN1B gene are associated with epileptic disorders such as Dravet syndrome and GEFS+, as well as cardiac conditions like Brugada syndrome, highlighting its physiological importance in both the nervous and cardiac systems[1][2][3][4][5].
- Other names
- Sodium channel subunit beta-1Sodium channel regulatory subunit beta-1SCN1BNavβ1Beta-1 subunit of voltage-gated sodium channel
02
Mechanism of action
Modulation of sodium channel inactivation and recovery from inactivation Alteration of channel-mediated sodium current Influence on neuronal and cardiac action potential characteristics Regulation of cell surface expression of sodium channel complexes
03
Biological functions
Modulation of sodium channel gating and kineticsNeuronal migration and pathfindingAction potential generation and propagationRegulation of cardiac and neuronal excitabilityStimulation of neurite outgrowth
04
Disease associations
Epileptic encephalopathies (e.g., Dravet syndrome, GEFS+)Cardiac arrhythmias (e.g., Brugada syndrome)Sudden death due to arrhythmiaOther neurological and cardiac disorders
05
Safety considerations
Risk of severe epilepsy or arrhythmias from loss-of-function or gain-of-function mutationsPotential exacerbation of symptoms when using sodium channel blockers in individuals with known mutationsSudden cardiac death risk in vulnerable patients
06
Interacting drugs
None directly, but drugs affecting voltage-gated sodium channels (e.g., anticonvulsants like phenytoin, carbamazepine, and antiarrhythmics) may indirectly affect function by modulating the parent channel complex
07
Biomarkers
SCN1B gene mutations as diagnostic biomarkers for Dravet syndrome, GEFS+, or Brugada syndrome in genetic testing
Beyond the preview
Go deeper on Sodium channel protein type 1 subunit beta (SCN1B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sodium channel protein type 1 subunit beta (SCN1B).